Milestones and Royalties. .................................................................9 4.1 Europe.........................................................................................10 4.2 Territory other than Europe....................................................................10 4.3 Duration of Royalty Obligations................................................................10 4.4 Royalty Rate if Generics Introduced............................................................11 4.5 Sales by Sublicensees..........................................................................11 4.6 Royalty Payments and Reports...................................................................11 4.7 Taxes..........................................................................................11 4.8 Blocked Currency...............................................................................12 4.9 Payments to or Reports by Affiliates...........................................................12 4.10 No Multiple Royalties..........................................................................12 ARTICLE 5 CONFIDENTIALITY............................................................................12 5.1 Confidentiality; Exceptions....................................................................12 5.2 Authorized Disclosure..........................................................................12 5.3 Survival.......................................................................................13 5.4 Termination of Prior Agreement.................................................................13 5.5 Publications...................................................................................13 ARTICLE 6 OWNERSHIP OF INTELLECTUAL PROPERTY AND PATENT RIGHTS.......................................13 6.1 Ownership......................................................................................13 6.2 Disclosure of Patentable Inventions............................................................14 6.3 Patent Filings.................................................................................14 6.4 Third Party Patent Rights......................................................................15 6.5
Milestones and Royalties. In consideration of the rights granted under Article 2 for the First Licensed Product, ADCT shall make the milestones and royalties payments detailed in Annex 2. In consideration of the rights granted under Article 2 for the Second Licensed Product, ADCT shall make the milestones and royalties Payments detailed in Annex 3, or in Annex 4 if the Second Licensed Product binds to the [***] Target.
Milestones and Royalties. With respect to each [ * ] obtained by Millennium, the terms of Article 6 shall apply.
Milestones and Royalties. (A) If any Compound screened by Aurora under the Research Program, or any derivative thereof, is developed and commercialized as a drug product, or any assay development or screening work performed by Aurora under this Agreement otherwise directly or indirectly leads to the development and commercialization of any drug products (collectively, "Products"), Aurora shall be entitled to receive from Sequana, subject to paragraph (c) below, *** of all license fees, milestone payments and other fees and compensation received by Sequana from third parties (if any) with respect to such Products and (ii) royalties on Net Sales of such Products equal to the *** (if any) with respect to such Products; provided, however, that with respect to any Product, the amounts to which the percentages under the foregoing clauses (i) and (ii) are applied shall be *** in connection with the discovery, development or commercialization of such Product.
Milestones and Royalties. As further consideration for the Technology License, QIAGEN will:
Milestones and Royalties. Notwithstanding anything to the contrary contained in the Product License, the sublicense granted to Sublicensee under Section 1 of this Sublicense shall be subject to only the milestone and royalty payments set forth in Article 4 of the Collaboration License Agreement and Sublicensee shall have no payment obligations under the Product License or this Sublicense.
Milestones and Royalties. PDI or Parent (as applicable) shall deliver the Future Payments on the terms and subject to the conditions of the Contingent Consideration Agreement in substantially the form attached hereto as Exhibit C (the “Contingent Consideration Agreement”).
Milestones and Royalties. The payment of Milestone Payments and Royalties shall not be affected by any such Bxxxxxx Sublicense, such Milestone Payments being payable by Bxxxxxx to MediGene pursuant to the terms of this Agreement regardless of whether any sales are made by Bxxxxxx, its Affiliates or any Sublicensee, and such Royalties being payable by Bxxxxxx pursuant to the terms of this Agreement regardless whether the sales that are made are made by Bxxxxxx, its Affiliates or any Sublicensee.
Milestones and Royalties. 3.1 In consideration of granting the rights described in Article 2, and subject to the provisions of Articles 3 and 4.1, Cytogen shall pay to DRAXIMAGE milestones aggregating Two Million Dollars ($2,000,000) to be paid by Cytogen in cash as follows:
Milestones and Royalties. For purposes of calculating milestone and royalty payments pursuant to Article 7 and Article 8 of the Agreement and paragraph 6(c)(i) below, all Other Compounds and products containing Other Compounds shall be deemed to be SMC Licensed Products containing Collaboration Compounds to which the following terms of the Agreement are applicable:
